구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Product (Anti-Tumor Necrosis Factor Alpha Drug, Anti-Tumor Necrosis Factor Alpha Drug (Product)) R.Bos·Rheumatoid Arthritis 158 trials |
|---|---|
Overview Program | Anti-Tumor Necrosis Factor Alpha Drug (Product) |
Overview Company | R.Bos |
Overview Modality | ANTIBODY |
Overview Target | Rheumatoid Arthritis |
Overview Indication | Rheumatoid Arthritis |
Overview Phase | APPROVED |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Established |
Overview Approval status | Approved (flag incomplete) |
MoA Mechanism | target toxicity, as further supported by transcriptomic analysis revealing downregulation of fibrosis- and metabolism-related pathway |
MoA Biomarker | biomarkers, and well-designed clinical trials with vascular or cardiovascular endpoints are required before c |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | thrombocytopenia and adverse events primarily limited to abdominal pain, nasopharyngitis, headac |
Clinical Safety signal | thrombocytopenia and adverse events primarily limited to abdominal pain, nasopharyngitis, headac |
Clinical Selected reported efficacy | Response 0.07447% |
Clinical Result source | ClinicalTrials.gov NCT01981473 |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT01981473 |
Preclinical Animal (cat.) | Mouse |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Product (Anti-Tumor Necrosis Factor Alpha Drug, Anti-Tumor Necrosis Factor Alpha Drug (Product)) R.Bos·Rheumatoid Arthritis 158 trials |
|---|---|
Overview Program | Anti-Tumor Necrosis Factor Alpha Drug (Product) |
Overview Company | R.Bos |
Overview Modality | ANTIBODY |
Overview Target | Rheumatoid Arthritis |
Overview Indication | Rheumatoid Arthritis |
Overview Phase | APPROVED |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Established |
Overview Approval status | Approved (flag incomplete) |
MoA Mechanism | target toxicity, as further supported by transcriptomic analysis revealing downregulation of fibrosis- and metabolism-related pathway |
MoA Biomarker | biomarkers, and well-designed clinical trials with vascular or cardiovascular endpoints are required before c |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | thrombocytopenia and adverse events primarily limited to abdominal pain, nasopharyngitis, headac |
Clinical Safety signal | thrombocytopenia and adverse events primarily limited to abdominal pain, nasopharyngitis, headac |
Clinical Selected reported efficacy | Response 0.07447% |
Clinical Result source | ClinicalTrials.gov NCT01981473 |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT01981473 |
Preclinical Animal (cat.) | Mouse |
추천 비교
추천 비교